Ontology highlight
ABSTRACT:
SUBMITTER: Glitza IC
PROVIDER: S-EPMC4306428 | biostudies-literature | 2014 Sep
REPOSITORIES: biostudies-literature
Glitza Isabella C IC Davies Michael A MA
Chinese clinical oncology 20140901 3
Until recently, treatment options for patients with metastatic melanoma were very limited. This landscape has evolved dramatically since the discovery of activating mutations in the <i>BRAF</i> gene in ~45% of cutaneous melanomas. Vemurafenib, dabrafenib, and trametinib have all received regulatory approval for the treatment of metastatic melanoma patients with a <i>BRAF<sup>V600</sup></i> mutation. Based on the necessity to document the presence of a <i>BRAF<sup>V600</sup></i> mutation to presc ...[more]